Biocon and Mylan launch biosimilar Lantus in USA

1 September 2020

Biocon Biologics India, a fully integrated ‘pure play’ biosimilars company and a subsidiary of Biocon (BSE: 532523) and Mylan (Nasdaq: MYL) yesterday announced the US launch of Semglee (insulin glargine injection) in vial and pre-filled pen presentations, approved to help control high blood sugar in adult and pediatric patients with type 1 diabetes and adults with type 2 diabetes.

News of the launch sent Biocon’s shares up 4.2% to 375., while Mylan stock edged up less than 1% to $16.38.nch saw Biocon’s shares close up 4.2% at 375.00 rupees

Semglee, which received final approval from the US Food and Drug Administration (FDA), has an identical amino acid sequence to French pharma major Sanofi’s (Euronext: SAN) Lantus and is approved for the same indications. It is not recommended for the treatment of diabetic ketoacidosis.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK